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The growing incidence of obesity, hypertension, and diabetes, coupled with the aging of the population, is increasing the prevalence
of renal diseases in our society. Chronic kidney disease (CKD) is characterized by persistent inﬂammation, ﬁbrosis, and loss of renal
function leading to end-stage renal disease. Nowadays, CKD treatment has limited eﬀectiveness underscoring the importance of the
development of innovative therapeutic options. Recent studies have identiﬁed how epigenetic modiﬁcations participate in the
susceptibility to CKD and have explained how the environment interacts with the renal cell epigenome to contribute to renal
damage. Epigenetic mechanisms regulate critical processes involved in gene regulation and downstream cellular responses. The
most relevant epigenetic modiﬁcations that play a critical role in renal damage include DNA methylation, histone modiﬁcations,
and changes in miRNA levels. Importantly, these epigenetic modiﬁcations are reversible and, therefore, a source of potential
therapeutic targets. Here, we will explain how epigenetic mechanisms may regulate essential processes involved in renal
pathology and highlight some possible epigenetic therapeutic strategies for CKD treatment.
1. Introduction
The term “epigenetics”was ﬁrst used by ConradWaddington
in 1942 to describe the eﬀect of gene-environment interac-
tions on the expression of particular phenotypes [1–3]. Not
only does gene expression depend on the diﬀerent changes
in the cellular machinery surrounding DNA expression but
also the environment exerts a powerful inﬂuence on the gene
expression. It can be said that epigenetic changes inﬂuence
the gene expression, but it is only a part of the variability that
exists in a cell when it comes to expressing information con-
tained in DNA. Epigenetic mechanisms are fundamental for
normal development and maintenance of tissue-speciﬁc gene
expression through changes on chromatin structure, func-
tion regulation, and posttranscriptional mechanisms. These
epigenetic modiﬁcations include DNA methylation (cytosine
methylation), histone posttranslational modiﬁcations, and
miRNAs (Figure 1) [4].
Epigenetics has recently been shown to have impact on
human health and disease susceptibility. Although there is a
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genetic predisposition for the development of chronic kidney
disease (CKD), genetics alone falls short of explaining the
complex disease progression across individual CKD patients
[5]. Many factors altered in CKD patients, such as uremic
toxins, oxidative stress, and inﬂammation, as well as changes
in metabolic states, like hyperglycemia in diabetes, can
induce epigenetic modiﬁcations by regulating gene expres-
sion and altering the immune response and therefore con-
tribute to renal disease progression [6]. The identiﬁcation
of these epigenetic changes is a recent and innovative ﬁeld
of research in renal pathology [7]. In this review, we summa-
rize the epigenetic mechanisms that could regulate critical
processes in renal pathology, including inﬂammation and
extracellular matrix accumulation (ECM), and oﬀer an
account of potential therapeutic strategies based on epige-
netic targets for CKD treatment (Figure 1).
1.1. DNA Methylation and Kidney Diseases. DNA methyla-
tion is a common epigenetic mechanism used by cells to
express or silence a gene [8]. DNA methylation mainly
occurs on the cytosine residues of CpG (cytosine-phos-
phate-guanine) sites [9], and in mammalians, 60-90% of
them are methylated [10]. DNA methylation patterns are
speciﬁc of tissue/cell type maintaining gene expression
states [11]. Thus, as a paradigm, hypomethylated DNA is
associated with active transcription, whereas hypermethy-
lated DNA is packaged in inactive chromatin (heterochro-
matin) [12].
DNA methylation is catalyzed by a family of enzymes
named DNA methyltransferases (DNMTs), which transfer
a methyl group from S-adenosyl methionine (SAM) to the
ﬁfth carbon of cytosine at the dinucleotide CpG. DNMTs
can be classiﬁed in two groups: (1) maintenance DNMTs
such as DNMT1, which shows a preference for hemimethy-
lated DNA and functions during DNA replication, and (2)
de novo DNMTs including DNMT3A and DNMT3B, which
methylate DNA (unmethylated or methylated) at an equal
rate [13–15]. In addition, DNA demethylation can occur
passively or as a result of the action of enzyme dioxygenases
from the TET protein family (TET1, TET2, and TET3) that
generate sequential DNA methylation cytosine changes,
such as 5-hydroxymethylcytosine (5hmC), 5-formylcytosine
(5fC), and 5-carboxylcytosine (5caC), culminating in excision
by base-excision repair of glycosylases such as TDGs (thymine
DNA glycosylases), followed by DNA repair to replace the
modiﬁed cytosines by nonmethylated cytosines [16].
In the pathological context, aberrant DNA methylation
and consequent deregulated gene expression could be
involved with the pathogenesis of many diseases, including
cancer, cardiovascular pathologies, metabolic disorders (obe-
sity and diabetes mellitus), or renal diseases [17–21]. In the
last years, several studies carried out in CKD patients
revealed that systemic DNA methylation patterns correlate
with the rate of kidney function decline [22, 23].
A recent epigenome-wide association study (EGWAS) in
whole-blood DNA of patients from Atherosclerosis Risk in
Communities (ARIC) and Framingham Heart (FHS) studies,
analyzed using regression models with residualized methyla-
tion β-values as the independent variable, showed a statisti-
cally signiﬁcant association between the DNA methylation
level in speciﬁc CpG sites (e.g., cg23597162 in JAZF1;
cg19942083 in PTPN6/PHB2; and cg17944885 in ZNF788/
ZNF20) and the reduction in glomerular ﬁltration rate
(eGFR), prevalence and incidence of CKD (cg17944885 and
cg19942083 in PTPN6/PHB2), or renal ﬁbrosis (cg12065228
in PQLC2, intergenic cg19942083 near PTPN6/PHB2,
Environment
Food intake
Lifestyle
Environmental 
stress
Genome
Genetic variants
Healthy kidney
Epigenetic modification mechanisms
Metabolism deregulation
Oxidative stress
Mechanical stress
Cytokines
Chemokines
AKI
Inflammation
Fibrosis
Diabetic nephropathy
Me
DNA methylationHistone modifications
DNMTs
Me
Me
Me hMe
Me
MeMe
Ac
Ac
HDACs
HATs
HDMs
HMTs
TETs
MicroRNAs
Tr
an
sc
rip
tio
n Processing
Drosha
Dicer
miRNA RISC
Damaged kidney 
CKD
ESRD
Hyperglycemia
Hypertension
Hypomethylation
CTGF
IGBP1
PXR
CLDN1
SMAD6
H3K9/14Ac and H4K5,8,12Ac at TNF-훼, COX-2 
Ac
BET 
proteins
Cr
P
5’AAAAA-3’
mRNA target
H3K9me3 훼-SMA
H3K4me Col1a1, PAI-1
TGF-훽
H2AX phosphorylation
Histone crotonylationat PGC-1 
miR-146a
miR-20a
miR-192
miR-21
miR-214 
miR-21
miR-146b 
PPAR-γ
IL-6, IL-8 
miR-30
miR-29
miR-3201
miR-1273a
Changes in gene expression Pro-fibrotic and pro-inflammatory genes
Anti-fibrotic and anti-
inflammatory genes
Hypermethylation
RASAL1
DNMT1/3A
Calcitonin
MMP-9
TIMP-1
CLDN18
Figure 1: The main epigenetic changes associated with clinical and experimental renal damage such as DNAmethylation (DNAme), histone
posttranslational modiﬁcations, and miRNAs.
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cg12116137 in PRPF8, cg09022230 in TNRC18, and
cg27660627 in ANKRD11). Moreover, they also found a
signiﬁcant enrichment of eGFR-associated CpGs in regions
that bind the transcription factors (TFs), like EBF1, EP300,
and CEBPB [24]. Accordingly, DNA methylation in speciﬁc
CpG sites was associated with eGFR decline and ﬁbrosis in
diabetic American Indians [25].
DNA methylation patterns in speciﬁc genes could be
relevant as potential biomarkers. The connective tissue
growth factor (CTGF or CCN2) is a proﬁbrotic factor, a
potential biomarker of renal damage in diabetes, and a
potential therapeutic target, as demonstrated in experimental
models of renal injury [26, 27]. In diabetic nephropathy
(DN), demethylation of the CTGF gene promoter correlates
with low eGFR [28, 29]. MTHFR DNA methylation levels
were higher in end-stage renal disease (ESRD) patients than
in controls and associated with a decreased eGFR [30]. A
study carried out in patients with type 1 diabetes (T1D)
showed a decrease in IGFBP1 DNA levels from peripheral
blood samples compared to normal glucose tolerance sub-
jects, which could be associated with the increased circulating
levels of IGFBP-1 in those patients [31].
Most of the knowledge about DNA methylation on renal
damage came from studies in DN. Experimental studies eval-
uating tubular cells of diabetic mice have found an aberrant
DNA hypomethylation in genes involved in glucose metabo-
lism, such as Agt (a marker of renal damage in diabetes) and
Hnf4a (a transcription factor regulating transporters for reab-
sorption). In contrast, other genes were hypermethylated, such
as cldn18 [32].Moreover, increased expression of the pregnane
X receptor caused by aberrant demethylation of its promoter
was also described [33], although the biological meaning of
these ﬁndings remains to be determined. Studies carried out
in streptozotocin- (STZ-) induced diabetic mice showed hypo-
methylation of cldn1-CpG regions and Sirt1 overexpression
leading to higher methylation levels of these regions. In paral-
lel with these epigenetic changes, the levels of cldn1 mRNA
expression were lower in parietal epithelial cells from diabetic
Sirt1 transgenic mice compared toWT cells [34]. Additionally,
several studies carried out in whole blood samples from DN
patients have identiﬁed diﬀerentially methylated genes
(NRBF2, RUNX3, DAPK3 UNC13B, and DOC2A) associated
to diﬀerent processes such as transcription regulation, inﬂam-
mation, apoptosis, or exocytosis [35, 36]. In another study, a
signiﬁcant negative correlation between methylation levels of
targeted genes (TIMP-2 and AKR1B1) and albuminuria levels
was found in early DN [37].
DNA methylation also participates in the regulation of
ECM-related genes. In human kidney samples from CKD
patients, diﬀerentially methylated regions located in putative
enhancers have been described. Genes around these regions
include COL IVA1/2 (a key component of ECM) transform-
ing growth factor beta (TGF-β) and smad proteins, with
TGF-β/Smad being a key signalling pathway involved in
ECM regulation. In the case of Smad proteins, SMAD3 and
SMAD6 cytosine methylation changes were correlated with
gene transcription levels [38]. Hyperhomocysteinemia
(HHcy) is prevalent in patients with CKD and ESRD and is
characterized by an abnormally high level of homocysteine
in the blood. In experimental hyperhomocysteinemia-
induced renal damage, DNA hypermethylation and
upregulation of dnmt1 and dnmt3a were followed by gene
expression changes in crucial proteins involved in ECM
regulation, including matrix metalloproteinase-9 (MMP-9)
(an enzyme that participates in collagen degradation) and
downregulation of MMP inhibitors, including tissue inhibi-
tor of metalloproteinase- (TIMP-) 1 and -2. Besides, in
injured kidneys there was an imbalance in the methylation
status of mmp9 and timps, leading to increased collagen
deposition. Importantly, the treatment of these animals with
a DNA methylation inhibitor, 5-aza-2-deoxycytidine (5-
Aza), restored matrix-degrading enzyme MMP-9/TIMP
imbalance and ameliorated renal ﬁbrosis [39]. Hyperme-
thylation of the rasal1 gene causes increased Ras-GTPase
activity in ﬁbroblasts, leading to proliferation and ﬁbrosis
in the kidney [40]. In the experimental model of unilateral
ureteral obstruction (UUO), TGF-β induces suppression of
Klotho, a known renal antiﬁbrotic protein by hypermethy-
lation of its promoter through induction of dnmt1 and
dnmt3a [41].
DNA methylation can also modulate the inﬂammatory
process in the injured kidney. In dialysis patients, global
DNA hypermethylation (total DNA 5-mc) in blood samples
was associated with elevated inﬂammatory markers as ferri-
tin and procalcitonin, the latter being a marker of inﬂamma-
tion due to bacterial infections [42]. In hemodialysis patients,
global DNA methylation was higher than in hemodiaﬁltra-
tion patients and DNA methylation is most elevated in
inﬂamed patients [43]. Experimental studies described
altered DNA methylation status of a speciﬁc CpG within
the IFN response element resident in the promoter region
of the C3 gene in response to hypoxia and oxidative stress
upon ischemia-reperfusion (I/R) injury in rats [44]. In a
mouse model of I/R, the analysis of the global level of the
DNA hydroxymethylation mark (5-hydroxymethylcytosine
(5hmC)) assessed by immunohistochemistry and dot blot
showed an apparent decrease in 5hmC levels in ischemic
mouse kidney [45]. I/R injury alters the 5hmC levels at spe-
ciﬁc gene loci at proximal promoter regions of the proinﬂam-
matory genes cxcl10 and ifngr2 (non-ligand-binding beta
chain of the gamma interferon receptor). This decrease in
5hmC levels is related to an increase in gene expression of
cxcl10 and ifngr2. These alterations were associated with
dysregulation in TET protein expression, proteins that
catalyze the oxidation of 5mC into 5hmC [45]. In systemic
sclerosis (SSc), a rare connective tissue disease characterized
by chronic inﬂammation and ﬁbrosis with deleterious
eﬀect in the kidney, DNA hypomethylation in CD4+ T-
lymphocytes from SSc patients decreased the expression
of methylation genes such as DNA methyltransferases
(DNMT)1 and methyl-CpG-binding domain proteins
(MBD)3 and MBD4 [46, 47]. DNA methylation also partici-
pates in acute kidney injury (AKI) and renal transplantation.
Methylation of the kallikrein promoter has been found in
patients with established acute kidney injury (AKI) [48].
Additional, aberrant hypermethylation of the calcitonin
gene promoter is more frequent in kidney transplant
recipients [49].
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1.1.1. Demethylating Treatments. Together, these studies
indicate that monitoring or targeting the epigenome could,
therefore, reveal new therapeutic approaches in CKD and
open up paths to biomarker discovery and targeted ther-
apy. Demethylating agents could be useful therapeutic
approaches. Currently, two demethylating drugs are in
clinical use, 5-azacitidine and decitabine, for the treatment
of speciﬁc forms of myelodysplastic syndrome and acute
myeloid leukemia [50]. In an experimental DN model
(db/db mouse), treatment with 5-azacitidine or decitabine
attenuated the increased expression of dnmt1, markedly
diminished albuminuria, and restored podocyte function
[51]. Unfortunately, 5-azacitidine and decitabine have
signiﬁcant adverse eﬀects because of their broad demethylat-
ing activity and cytotoxicity. Consequently, more speciﬁc and
less toxic drugs are needed to elucidate the therapeutic
potential of these inhibitors.
Another therapeutic experimental approach is the
antihypertensive agent hydralazine, used in clinical therapy
since the middle of the last century [52]. Hydralazine has
been proven to attenuate renal ﬁbrosis in a model of
ischemia-reperfusion by inducing expression of hydroxylase
TET3, which catalyzes hydroxymethylation and subse-
quently promotes demethylation of genes such as rasal1
[53]. Other compounds presented demethylating activity,
for example, Rhein, a plant-derived anthraquinone which
displays strong antiﬁbrotic properties in the experimental
model of UUO, probably by reverse Klotho DNA hyperme-
thylation [54] (Figure 1).
1.2. Histone Modiﬁcations and Kidney Diseases. Posttran-
scriptional histone modiﬁcations (PTM) play a critical role
in chromatin structure acquiring two conﬁgurations, one
more closed (heterochromatin) and inactive and another less
compact (euchromatin) and associated with active gene tran-
scription. These modiﬁcations include acetylation, methyla-
tion, ubiquitination, propionylation and crotonylation of
lysine residues; methylation, ribosylation and citrullination
of arginine residues; and the phosphorylation and glycosyla-
tion of serines and threonines [55]. Histone modiﬁcations
can occur within the folded domain of the histones or in
the N- and C-terminal domains that extend beyond the
nucleosome [56, 57]. Some of these modiﬁcations exert an
activating function (such as H3K4me3, AcH3, AcH4, and
AcH3K9) facilitating the opening of the chromatin and the
union of the transcriptional machinery, while other modiﬁ-
cations are repressive (such as H3K27me3, H3K9me2/3,
and H4K20me3,), allowing the compaction of chromatin
and preventing the union of the transcriptional machinery
(Figure 1).
The adding or removing of histone marks is carried out
by a group of enzymes named (1) “writers,” responsible for
adding (“writing”) diﬀerent epigenetic marks such as HAT
(histone acetyltransferase), which adds acetyl groups to
histone tails, (2) “erasers,” responsible for the removal of
epigenetic marks of the histone, such as histone deacetylases
(HDACs) or histone demethylases (HDMs), and (3)
“readers,” whose function is to recognize the diﬀerent
epigenetic marks added in the histones. Among the reader
proteins, one of the most relevant are the BET proteins,
which contain bromodomains that recognize acetylated
lysine residues in the histone tails [55, 58]. Next, we will
discuss how these enzymes and epigenetic modiﬁcations
could participate in renal pathology.
1.2.1. Histone Acetylation. Histone acetylation reduces the
net positive charge of histones and weakens interactions with
DNA. This perturbation in chromatin facilitates DNA tran-
scription. The acetylation process occurs when the acetyl
group (COCH3) is transferred from acetyl-coenzyme A (ace-
tyl-CoA) to lysine residues, by a process regulated by histone
acetyltransferases (HATs) [59]. By contrast, the acetylated
residues can be recovered by three classes of histone deacety-
lases (HDAC): class I HDACs which are zinc-dependent and
located in the nucleus, class II HDACs which are also zinc-
dependent but are present in the nucleus and cytoplasm,
and class III HDACs called sirtuins (Sirt 1-7) which depend
upon NAD+ for their activity and are present in the nucleus,
cytoplasm, and mitochondria [59].
Many studies have found that histone acetylation partic-
ipates in experimental renal ﬁbrosis (Figure 2). Studies done
in the unilateral ureteral obstruction (UUO) model have
shown that treatment with various HDAC inhibitors, such
as trichostatin A or the selective class I HDAC inhibitor
MS-275, reduced renal ﬁbrosis by diminishing proﬁbrotic
markers (α-smooth muscle actin (SMA)) and accumulation
of ECM proteins, including ﬁbronectin and type I collagen
[60–63]. In these studies, the most relevant downstream
ﬁbrotic-related mechanisms were inhibited by HDAC
inhibition, including TGF-β/Smad, EGFR, and STAT3 sig-
nalling pathways [60] or JNK-dependent Notch-2 signalling
pathways [61–63]. In experimental diabetes induced by
streptozotocin injection in mice, HDAC inhibition with
trichostatin A diminished proﬁbrotic gene overexpression.
Moreover, in vitro studies in rat tubular epithelial cells
(NRK52-E cell line) showed that HDAC inhibition by the
HDAC inhibitor Trichostatin A (TSA), valproic acid, SK-
7041, or N-acetylcysteine or gene silencing of HDAC-1/2
restored TGF-β1-induced phenotypic changes, including
induction of α-SMA and loss of epithelial markers [64], sug-
gesting that histone acetylation could also be involved in
renal ﬁbrosis by modulating the epithelial phenotype.
HDAC inhibitors have also been involved in the regula-
tion of renal inﬂammation (Figure 2). In a model of lupus
nephritis, the HDAC inhibitor ITF2357 diminished the
proinﬂammatory gene expression of il6, il-1β, and the sys-
temic lupus erythematosus (SLE) serum biomarker IgG2a
[65]. In Adriamycin-induced renal ﬁbrosis, two HDAC
inhibitors, TSA and valproic acid, reduced the expression
of the chemokines mcp1 and mip1β and diminished renal
macrophage inﬁltration [66]. Similar eﬀects of both
HDAC inhibitors were described in the UUO model by
reduction of CSF-1 in renal tubule interstitial space, a
chemokine known to be involved in macrophage inﬁltra-
tion [61]. Moreover, TSA also decreased juxtaglomerular
hyperplasia in damaged kidneys and the degree of ﬁbrosis
analyzed by protein levels of ﬁbronectin and collagen I.
On the other hand, TSA reduced the percentage of
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FOXP3+IL-17+ cells and the genic expression of foxp3 and
rorγt, key transcription factors involved in the modulation
of Th17 diﬀerentiation [63].
Histone acetylation can also contribute to the inﬂamma-
tory process associated with diabetes (Figure 2). In blood
monocytes of diabetic patients, the acetylation of histones
H3K9/14Ac and H4K5,8,12Ac in promoters of inﬂammatory
genes such as TNF-α and COX-2 was increased [67]. In
models of acute kidney injury, TSA also exerts anti-
inﬂammatory actions, including reduction in cytokine and
chemokine expression through an increase of the anti-
inﬂammatory protein microglia/macrophage WAP domain
protein [68] and a decrease in NF-κB signalling [69].
There are now some ongoing clinical trials studying
the eﬀect of diﬀerent HDAC inhibitors, such as belinostat,
entinostat, vorinostat, and panobinostat, in renal tumors
[70–72]. Previous studies in other types of tumors, including
lymphoma and myeloma, have shown beneﬁcial eﬀects,
whereas these drugs do not have enough eﬀective activity in
the treatment of renal tumors [73–75]. Thus, these data
indicated that future research with epigenetic modulators in
renal cancer patients would be necessary.
1.2.2. Role of BET Proteins in Protein Acetylation. The family
of bromodomain and extraterminal (BET) proteins is
composed of four members: BRD2, BRD3, BRD4 (ubiqui-
tously expressed), and BRDT. BET proteins contain a
tandem of two conserved N-terminal bromodomains
(BD1 and BD2) and an extraterminal domain. BD inter-
acts with acetylated lysine residues in histones acting as
an epigenetic “reader” [76]. Studies on the cancer ﬁeld
have described that BRD4 contributes to the recruitment
of the positive transcription elongation factor b (P-TEFb)
complex (heterodimer of CDK9 and cyclin T1, T2, or K)
to the promoter region and activates RNA polymerase II-
dependent (RNAPII) transcription. BRD4 binds to acety-
lated histones in the enhancer or promoter regions of
oncogenes and inﬂammatory genes and by this mechanism
participates in malignancies and inﬂammatory diseases
[77]. Intensive pharmacological research has focused on the
design of BET protein inhibitors (iBETs). One of the earliest
developed and best studied is JQ1. This iBET was devel-
oped by Jun Qi, a researcher belonging to Chris French’s
group [78], who demonstrated that JQ1 competes for the
bromodomain-binding pocket and displaces BET proteins
from the binding to acetylated lysine residues located in
histones. This interrupts the remodelling of chromatin and
prevents the expression of certain genes [78]. First studies
were done in experimental proliferative pathologies, includ-
ing midline carcinoma and hematological malignances,
showing that JQ1 regulates cell proliferation and apoptosis,
by reducing the expression of cancer-promoting genes, such
as c-Myc and bcl-2, two target genes of BRD4 [79], but
now, many preclinical studies have shown its beneﬁcial
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eﬀects in diﬀerent pathologies. In a murine model of polycys-
tic kidney disease, iBET JQ1 delayed cyst growth and
preserved renal function, by inhibiting c-Myc gene and cystic
epithelial cell proliferation [80]. Many in vitro studies have
described that iBETs could exert anti-inﬂammatory actions,
by inhibiting proinﬂammatory gene expression [81–83].
Our group had recently described that in cultured tubular
epithelial cells stimulated with TNF-α, treatment with JQ1
decreased the expression of several genes associated with
inﬂammatory processes and immune response [84]. More-
over, in diﬀerent models of renal damage (UUO, immune-
mediated glomerulonephritis, and angiotensin II-induced
renal damage), we showed that JQ1 treatment inhibited renal
inﬂammation [84]. By chromatin immunoprecipitation
experiments, we described that the mechanism involved in
the anti-inﬂammatory actions of JQ1 is mediated by the
displacement of BRD4 binding to acetylated histone H3 in
the promoter region of several proinﬂammatory genes (such
as IL-6, CCL-2, and CCL-5) (Figure 3). Additionally, the role
of BRD4 on the regulation of proinﬂammatory genes was
demonstrated by gene silencing [84]. Some preclinical stud-
ies have conﬁrmed this anti-inﬂammatory mechanism of
iBETs in other experimental pathologies [85, 86].
BET proteins can also bind to acetylated residues in other
proteins besides histones, including transcription factors,
regulating gene transcription. In an experimental diabetic
model of renal damage in db/db mice, increased acetylation
of transcription factors NF-κB and STAT3 were found,
showing that modulation of these signalling pathways could
be an important mechanism involved in renal inﬂammation
[87]. Many experimental studies have found that blockade
of the NF-κB pathway using speciﬁc inhibitors of this path-
way, or indirectly by drugs used in the clinic to treat CKD
patients, including blockers of the renin angiotensin system,
attenuates renal inﬂammation and ameliorates disease pro-
gression [88, 89]. The RelA NF-κB subunit is activated by
acetylation of lysine 310. Intensive research in the cancer
ﬁeld has unraveled the role of BET proteins in NF-κB
pathway regulation, demonstrating that BRD4 binding to
acetylated lysine-310 of RelA is essential for recruiting
BRD4 and CDK9 to the promoters of speciﬁc NF-κB target
genes [90–93]. We have described that JQ1 reduced RelA
nuclear levels in several models of renal damage and in
cultured cells in a proinﬂammatory environment and
thereby blocked NF-κB transcriptional activation and
downregulated several NF-κB-controlled genes, including
mcp1 and il17a [84], suggesting another mechanism contrib-
uting to the anti-inﬂammatory eﬀects of JQ1 in renal
damage. This mechanism has been conﬁrmed with other
iBETs [94], associated with inhibition of renal inﬁltration of
macrophages (Figure 3).
Studies blocking Th17 immune response by diﬀerent
approaches, including neutralizing antibodies against IL-
17A, soluble receptor, RORγt inhibitors, or genetically
modiﬁed mice, have demonstrated the involvement of this
immune response in chronic inﬂammatory diseases, includ-
ing immune and nonimmune experimental renal damage
[95–102]. BET proteins have been involved in the diﬀerenti-
ation of naïve CD4 T lymphocytes into Th17 cells [103]. In
two models of experimental renal damage, UUO, and
immune-mediated glomerulonephritis, we have found that
JQ1 treatment markedly diminished the presence of IL-
17A-expressing cells and the renal levels of IL-17A and other
Th17-related cytokines, such as ccl20 and csf1 [84]. Other
studies in diﬀerent pathologies support these data, as
described in collagen-induced arthritis and experimental
autoimmune encephalomyelitis [104, 105]. BET proteins
can modulate Th17 response by a direct eﬀect on il17a gene
expression. BRD4 and BRD2 bind to the regulatory region
of CNS2 that controls IL-17A transcription [99]. Moreover,
p300, a transcriptional coactivator that possesses bromodo-
minium and acetylase activity, binds to the promoter of the
il17a gene in murine Th17 cells, facilitating accessibility to
chromatin [106]. In summary, these data expand the neutral-
ization strategies of inﬂammatory eﬀects mediated by IL-17A
in the kidney using iBETs.
Several evidences suggest that iBETs can also present
antiﬁbrotic properties, as described in pulmonary ﬁbrosis
[104], liver [105], and cardiac damage [107]. The in vitro
experiments carried out in tubular epithelial cells stimulated
with TGF-β1 showed that the inhibition of BRD4 functions
by silencing their gene or treatment with JQ1 leads to a
decrease in the expression of ﬁbrotic genes, such as α-smooth
muscle actin and ﬁbronectin [108]. In the UUOmodel, treat-
ment with I-BET151 decreased ECM protein levels and the
activation of renal ﬁbroblasts [94]. Recent studies conﬁrm
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Figure 3: The action mechanism of the BET inhibitor JQ1, in the regulation of inﬂammation, Th17 response, and ﬁbrosis.
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the beneﬁcial eﬀect of JQ1 in ﬁbrosis and inﬂammation
consequent to the radiation used in radiotherapy in thoracic
cancer, by suppressing BRD4, c-MYC, collagen I, TGF-β,
p65, p-SMAD2, and p-SMAD3 after irradiation [109].
Diﬀerent pharmacological companies have developed
several iBETs; some of them are now being used in clinical
trials. Most of them have been used in diﬀerent types of can-
cer, such as breast cancer, small cell lung cancer, or prostate
cancer. For example, ABBV-075 presents a potential antineo-
plastic activity, leading to an inhibition of cell growth in
certain tumors [110]. TEN-010, from Roche, is tested in
patients with acute myeloid leukemia [75]. RVX000222, of
Resverlogix, was evaluated in patients with diabetes mellitus
type 2 and with cardiovascular diseases of high risk [75].
Future studies in renal diseases are required.
1.2.3. Histone Methylation. The process of histone methyla-
tion is related to the capacity to transfer one, two, or three
methyl groups (CH3) from the S-adenosyl-L-methionine
cofactor to lysine or arginine residues in the histone, gen-
erating mono-, di-, or trimethyl lysine/arginine residues.
This process is developed by a group of enzymes named
histone methyltransferases (HMTs) [111]. Some methyla-
tion in speciﬁc lysine modiﬁcations exerts an activating
function (H3K4me3) facilitating the opening of the chroma-
tin and the union of the transcriptional machinery, while
other modiﬁcations are repressive (H3K27me3, H3K9me2/
3, and H4K20me3,), allowing the compaction of chroma-
tin and avoiding the binding of the transcriptional
machinery [112].
Epigenetic modulation through PTMs such as histone
methylation can contribute to renal ﬁbrosis (Figure 1). In
the experimental UUO model in mice, H3K9me3 methyla-
tion was increased mainly in proximal tubules and myoﬁbro-
blasts of obstructed kidneys. In the same study, in vitro
analysis done in primary rat renal ﬁbroblasts and proximal
tubule cells (NRK-52e), TGF-β stimulation increased
H3K9me3 associated to induction of α-SMA expression
[113]. In rat mesangial cells, TGF-β increased proﬁbrotic
genes such as Col1α1 and PAI-1, associated to increased
H3K4me mark levels [114]. A study developed in a
podocyte-speciﬁc PTIP (a component of an H3K4 methyl-
transferase complex) knockout mice showed a reduction in
H3K4me associated with disease phenotype [115].
Recent studies indicate that H3K4me1/2/3 is essential for
the deregulation of key genes in the pathogenesis of DN
[116]. In this sense, modiﬁcations such as H3K4me and
H3K9me1 (associated with promoters of proinﬂammatory
genes) activated the expression of these genes in hyperglyce-
mic conditions [117]. Moreover, RelA NF-κB activation was
observed in endothelial cells in high-glucose conditions
associated with an increase of H3K4me1 in the p65 promoter
region [118, 119]. Accordingly, in an animal model of
nephrectomy in db/db mice, increased H3K4me2 renal levels
were associated with renal function loss and glomerulo-
sclerosis, and this eﬀect was diminished by treatment with
MCP-1/CCL2 antagonist (Spiegelmer mNOX-E36) [120].
In an ischemia-reperfusion injury model, the induction of
proinﬂammatory genes such as TNF-α and MCP-1 was
related to changes in histone proﬁles along these genes as
H3K4m3 or modiﬁcation in histone-modifying enzymes
(Set1 and BRG1) [121, 122].
1.2.4. Histone Phosphorylation. Phosphorylation occurs
predominantly on serine, threonine, and tyrosine side chains
or residues through a phosphoester bond formation; this
constitutes approximately 86.4%, 11.8%, and 1.8%, respec-
tively, of the human phosphor-proteome [123]. Also, this
phosphorylation can occur in less percentage in histidine,
lysine, and arginine through phosphoramidate bonds. His-
tone H2AX phosphorylation (γH2AX) at ser139 was induced
by ataxia telangiectasia-mutated (ATM) protein kinase, and
is a key marker of DNA damage because is accumulated in
DNA to recruit DNA repair complex [124, 125].
Previous studies described the role of γH2AX in oxidative
stress [126]. In an I/R renal injury model in mice, injured
kidneys presented elevated levels of γH2AX mainly located
in tubular epithelial cells [127]. Other studies developed in
a model of diabetic nephropathy induced by STZ in Nox1-
deﬁcient mice showed lower levels of γH2AX in glomerular
and tubular extracts in these KO mice compared to elevated
levels in diabetic mice, suggesting the possible role of oxida-
tive stress [128]. These results demonstrated the new role of
histone phosphorylation in the pathological process that
constitutes renal damage (Figure 1).
1.2.5. Histone Crotonylation. Histone crotonylation is a new
posttranscriptional histone modiﬁcation in lysine residues
(Kcr). Crotonate is a short-chain unsaturated carboxylic acid
(CH3CH=CHCO2H) that increases the crotonylation in
histones. The original structure and diﬀerent localization of
this histone modiﬁcation established an apparent variation
compared to lysine acetylation (Kac) [129, 130]. This type
of modiﬁcation has the function of activating promoters or
potential enhancers. Moreover, histone crotonylation is
increased in sex chromosomes and marks testis-speciﬁc
genes [129]. A recent study established the presence of
histone crotonylation in kidney damage after AKI using a
mouse model induced by folic acid administration [131].
PGC-1 is a transcription factor governing gene expression
of mitochondrial biogenesis and function, with a protective
role in renal diseases [132]. Enrichment of histone crotonyla-
tion at the pgc1 gene was found in response to inﬂammatory
cytokines such as TWEAK in tubular cells and in AKI kidney
tissue [131]. Crotonate administration to folic acid-injected
mice during 48 hours increased renal pgc1α and sirt3mRNA
and decreased ccl2 mRNA expression indicating that croto-
nate protects from experimental AKI (Figure 1) [131].
1.3. miRNAs and Kidney Diseases. miRNAs are a class of
endogenous single-stranded noncoding RNAs with a size
within 21-25 nucleotides. miRNAs are involved in post-
transcriptional regulation of gene expression by binding
to the 3′-untranslated regions (3′-UTRs) and 5′-untrans-
lated regions (5′-UTRs) of the target mRNAs and modulat-
ing its degradation [133–137]. These noncoding RNAs are
considered as epigenetic modulators due to their capacity of
modulating gene expression (Figure 1) [134].
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The miRNA levels have been investigated in patients with
CKD to elucidate their potential role as biomarkers in CKD
progression. A study carried out in a focal segmental glomer-
ulosclerosis (FSG) patient cohort showed increased levels of
miR-196a in urine of patients, relating this miRNA with pro-
teinuria and interstitial ﬁbrosis [138]. Furthermore, studies
performed in podocytes of FSG patients showed decreased
levels of miRNAs that belong to miR-30 related to a protec-
tive role of the inhibition of Notch1 and p53 pathways,
molecules involved in podocyte injury [139, 140]. Studies
carried out in proximal tubular epithelial cells and mesangial
cells showed that miRNAs belonging to the let-7 miRNA
family are positive regulators of renal ﬁbrosis due to their
capacity to upregulate the TGF-β1 receptor, increasing the
inﬂammatory TGF-β1 pathway [141, 142]. miR-21 has also
shown a proﬁbrotic eﬀect diminishing PPARα levels and,
consequently, lipid oxidation pathways in wild-type mice in
response to kidney injury [143]. In contrast, the miR-29
family has shown antiﬁbrotic eﬀects. In a STZ-induced
diabetic model developed in miR-29a transgenic mice, miR-
29a reduced glomerular ﬁbrosis and inﬂammation; these
results were conﬁrmed in miR-29 knockdown mice that
showed an increase in histone deacetylase activity inducing
renal dysfunction through podocyte apoptosis and protein-
uria [144, 145]. Furthermore, in the UUO model, miR-29
ultrasound-microbubble-mediated gene transfer reduced
renal ﬁbrosis [146]. Another antiﬁbrotic miRNA elucidated
in plasma of CKD patients was miR-16 [147].
miRNA-146b-5p has a protective role in reducing IL-6
and IL-8 levels in glomerular mesangial cells [148].
miRNA-663a and miRNA-423-5p have been related with
the NF-κB signalling pathway, an important target in the
development of lupus nephritis (LN) [149]. Moreover, miR-
3201 and miR-1273a are downregulated and associated with
endocapillary glomerular inﬂammation in LN patients [150].
Interestingly, miR-223-3p andmiR-93-5p are associated with
IL-6 levels in stage 4 CKD patients, while in stage 5 CKD
patients these miRNAs have been related with eGFR [151].
The role of miRNAs in AKI has been also investigated,
although its contribution to the disease is not well under-
stood. A study carried out in an experimental model of
cisplatin-induced AKI in mice showed an antiﬁbrotic role
of miR-122 inhibiting FOXO3 translocation and, therefore,
reducing inﬂammatory cell inﬁltration and increasing cell
viability and ﬁbrosis. In the same study, miR-34 was
described as proﬁbrotic miRNA since it is involucrate in
upregulating foxo3 levels [152]. miR-146a is also related to
the inﬂammatory process in AKI. This miRNA is upregu-
lated in inﬂammation states through IL-1/TLR activation of
NF-κB in cultured renal proximal tubular cells [153]. Other
miRNAs have been found to be downregulated in AKI and
proposed as protective miRNAs such as miR-17-92, whose
overexpression ameliorates I/R injury eﬀects on kidney
cells [154]. Additional investigations discovered upregulated
miRNAs such as miR-20a, miR-192, miR-187, miR-805, and
miR-194 in kidneys of C57BL/6 mice with I/R injury [155].
Diﬀerent miRNAs have been associated with DN
development. miR-192 has been shown to be increased in
renal biopsies of diabetic nephropathy patients [156] related
to ﬁbrosis and a decreased glomerular ﬁltration rate [157].
miR-192 is upregulated by TGF-β, triggered by the increase
in glucose levels, and is involucrated in TGF-β-induced col-
lagen expression. Other miRNAs have been related to TGF-
β/glucose increased levels. In a UUO model and tubular epi-
thelial cells, it has been observed that miR-21 is upregulated
by elevated TGF-β/glucose levels [158–160]. In the same
way, miR-214 and miR-21 expressions were upregulated
due to TGF-β increased levels and induced EMT in rat tubu-
lar epithelial cells (NRK52E) [161].
In contrast, high-glucose levels downregulate miR-29a
expression in HK2 cells, negatively regulating collagen IV
expression [162]. miRNA regulation of the inﬂammatory
process in DN patients is still unclear. miR-146a seems to
be protective against DN inﬂammation in an STZ-induced
diabetes model in miR-146a (−/−) mice, increasing renal
macrophage inﬁltration and upregulation of proinﬂamma-
tory genes such as IL-1β and IL-18 [163]. Consequently, with
the miR-29a eﬀects in ﬁbrosis, Chen et al. [164] reported in
type 2 diabetes in db/db mice anti-inﬂammatory and antiﬁ-
brotic functions of miR-29b, with results associated with
NF-κB-driven renal inﬂammation and T-bet/Th1-mediated
immune response. In contrast, Guo et al. [165] demonstrated
a miR-29c proinﬂammatory eﬀect in DN carried out by tris-
tetraprolin (TTP), targeting DN patients and immortalized
mouse podocytes (MPC5).
In any case, a recent review about miRNA in patients
with diabetic kidney disease identiﬁed miR-21-5p, miR-
29a-3p, miR-126-3p, miR-192-5p, miR-214-3p, and miR-
342-3p that are consistently dysregulated among diﬀerent
studies, and bioinformatics analysis revealed that all of them
play essential roles in diabetic kidney disease. Finally, a recent
meta-analysis from 20 datasets from human and animal
studies is aimed at recognizing consistently dysregulated
miRNAs in renal ﬁbrosis and identifying 5 upregulated
and 2 downregulated miRNA [166]. Thus, miR-1423p,
miR-2233p, miR-215p, miR-1425p, and miR-2143p were
shown to be consistently upregulated in several reports,
whereas miR-29c-3p and miR-200a-3p were downregu-
lated. However, the inclusion of diﬀerent etiologies,
together with the mixture of human and animal samples,
can hinder to obtain conclusive results.
2. Conclusion
Common mechanisms involved in CKD, including oxidative
stress, inﬂammation, and uremic toxins, can contribute to
the renal damage progression by inducing epigenetic modiﬁ-
cations, as we have reviewed here. One crucial clinical unmet
is the lack of eﬀective CKD treatment, with epigenetic drugs
being a source of potential and novel therapeutic options due
to the dynamic nature and reversibility of epigenetic modiﬁ-
cations. Many preclinical studies are using demethylating
agents, HDAC inhibitors, or BET protein inhibitors in exper-
imental renal diseases with successful results. On the other
hand, clinical studies have also been developed in patients.
HDAC inhibitors such as belinostat, entinostat, vorinostat,
and panobinostat and BET protein inhibitors, such as
ABBV-075 or TEN-010, have been tested in patients with
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several tumors, such as lymphoma and myeloma, with bene-
ﬁcial eﬀects whereas these compounds do not have enough
eﬀective activity in the treatment of renal tumors. Other
IBET RVX000222 has been used with good results in patients
with diabetes mellitus type 2 and cardiovascular diseases
closely related with CKD. However, future studies in renal
diseases are required to gain insight into epigenetic mecha-
nisms associated with the development of renal disease. Body
ﬂuids are an accessible source for epigenetic biomarkers.
DNAmethylation andmiRNAs have been studied in patients
as biomarkers in CKD progression, e.g., diabetic nephropa-
thy and focal segmental glomerulosclerosis, respectively. All
of these epigenetic modiﬁcations are a novel ﬁeld of study
to ﬁnd new targets that can be used as therapeutic
approaches and treatments in the diagnostic of CKD and in
the monitoring of the progression of renal disease.
In addition, considering the high susceptibility of the
genome to epigenetic changes mediated by environmental
factors during fetal development, it is of pivotal importance
to determine whether the maternal environment can
condition epigenetic changes in the fetus associated with
the development of renal pathologies during adulthood,
generating an important tool for the early detection and
prevention of kidney diseases.
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